RS51335B - Metoda lečenja akutnog rinosinusitisa - Google Patents

Metoda lečenja akutnog rinosinusitisa

Info

Publication number
RS51335B
RS51335B RSP-2010/0236A RSP20100236A RS51335B RS 51335 B RS51335 B RS 51335B RS P20100236 A RSP20100236 A RS P20100236A RS 51335 B RS51335 B RS 51335B
Authority
RS
Serbia
Prior art keywords
mometasone furoate
day
use according
treatment
amount
Prior art date
Application number
RSP-2010/0236A
Other languages
English (en)
Serbian (sr)
Inventor
Melvyn Bloom
Melvyn Danzig
Patricia Rohane
Heribert Staudinger
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51335(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of RS51335B publication Critical patent/RS51335B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
RSP-2010/0236A 2004-01-21 2005-01-19 Metoda lečenja akutnog rinosinusitisa RS51335B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53783004P 2004-01-21 2004-01-21

Publications (1)

Publication Number Publication Date
RS51335B true RS51335B (sr) 2011-02-28

Family

ID=34825945

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0236A RS51335B (sr) 2004-01-21 2005-01-19 Metoda lečenja akutnog rinosinusitisa

Country Status (16)

Country Link
US (2) US20050186144A1 (https=)
EP (2) EP1711164B1 (https=)
JP (2) JP4976139B2 (https=)
AT (1) ATE461693T1 (https=)
CA (1) CA2554064A1 (https=)
CY (1) CY1110620T1 (https=)
DE (1) DE602005020113D1 (https=)
DK (1) DK1711164T3 (https=)
ES (2) ES2426957T3 (https=)
HR (1) HRP20100208T8 (https=)
MX (1) MXPA06008240A (https=)
PL (1) PL1711164T3 (https=)
PT (1) PT1711164E (https=)
RS (1) RS51335B (https=)
SI (1) SI1711164T1 (https=)
WO (1) WO2005072704A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186144A1 (en) * 2004-01-21 2005-08-25 Schering Corporation Treatment methods
WO2008047149A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
RU2407558C1 (ru) * 2009-07-02 2010-12-27 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Способ лечения острого риносинусита у детей
TWI411121B (zh) * 2010-03-11 2013-10-01 Ind Tech Res Inst 光吸收層之製造方法及應用其之太陽能電池結構
US9744210B2 (en) 2012-12-27 2017-08-29 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with P-glycoprotein inhibitors
WO2017123933A1 (en) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
WO2020198232A1 (en) 2019-03-25 2020-10-01 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
IL299210A (en) * 2020-06-21 2023-02-01 Massachusetts Eye & Ear Infirmary Combined treatment of verapamil and methotrexate for the treatment of chronic rhinosinusitis
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
EP4566595A1 (en) * 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
CA2111002C (en) 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
ATE339952T1 (de) * 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6187765B1 (en) 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6465581B1 (en) * 2001-01-24 2002-10-15 The Goodyear Tire & Rubber Company Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ES2388537T3 (es) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
US20040081625A1 (en) * 2002-10-21 2004-04-29 Schering Corporation Nasal formulations for the treatment of allergies
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
US20050186144A1 (en) * 2004-01-21 2005-08-25 Schering Corporation Treatment methods
EP2651494B1 (en) 2010-12-13 2017-02-15 Pacesetter, Inc. Delivery catheter
US9106249B1 (en) 2014-09-04 2015-08-11 Semtech Corporation Calibration of a time-interleaved analog-to-digital converter

Also Published As

Publication number Publication date
DK1711164T3 (da) 2010-07-19
US20090022671A1 (en) 2009-01-22
PT1711164E (pt) 2010-06-28
JP2007518817A (ja) 2007-07-12
HRP20100208T1 (hr) 2010-05-31
ATE461693T1 (de) 2010-04-15
MXPA06008240A (es) 2006-08-31
ES2340777T3 (es) 2010-06-09
EP1711164B1 (en) 2010-03-24
CY1110620T1 (el) 2015-04-29
WO2005072704A2 (en) 2005-08-11
EP1711164A2 (en) 2006-10-18
EP2201936B1 (en) 2013-06-19
CA2554064A1 (en) 2005-08-11
DE602005020113D1 (de) 2010-05-06
SI1711164T1 (sl) 2010-06-30
EP2201936A1 (en) 2010-06-30
HRP20100208T8 (hr) 2010-06-30
JP4976139B2 (ja) 2012-07-18
PL1711164T3 (pl) 2010-09-30
JP2008110991A (ja) 2008-05-15
US20050186144A1 (en) 2005-08-25
ES2426957T3 (es) 2013-10-28
WO2005072704A3 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
JP5247265B2 (ja) 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US20090022671A1 (en) Treatment methods
US6723713B2 (en) Use of mometasone furoate for treating upper airway diseases
JP2011528355A (ja) 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
JP2002517450A (ja) 喘息の急性状態の予防または処置のための、ホルモテロールおよびブデソニドを含んでなる組成物の使用
US20130125882A1 (en) Method and composition for treating asthma and copd
HRP20140257T4 (hr) Uporaba ciklesonida za liječenje bolesti dišnih puteva
RU2678992C2 (ru) Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат
JP2014515360A (ja) フルチカゾンを含む鼻用医薬製剤
Wu et al. Pulmonary and nasal anti-inflammatory and anti-allergy inhalation aerosol delivery systems
Grzelewska-Rzymowska et al. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma
US9636350B2 (en) Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid
WO2000015234A1 (en) Compositions comprising corticosteroids for treating sinusitis or otitis media
JP2009545537A (ja) アンドラスト／グルココルチコイドの併用